Tiziana Life Sciences PLC - biotechnology company - Agrees deal with STC Biologics Inc for GMP manufacturing of TZLS-501, an anti-IL-6 receptor monoclonal antibody for the potential treatment of Covid-19. Tiziana is simultaneously developing an inhalation technology, in collaboration with Sciarra Laboratories, for the direct delivery of TZLS-501 into the lungs using a handheld inhaler or nebulizer for treatment of patients with Covid-19.
Current stock price: 107.00 pence
Year-to-date change: more than double from 41p at the start of the year
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.